Saturday, October 3, 2026

Tiger Global, SoftBank Cut Mega-Deals 95% as Global Venture Capital Reclaims Lead

Tiger Global and SoftBank slashed large-deal activity over 95% from 2021 to 2025, returning mega-round control to traditional venture firms globally. Just 1,440 companies raised $50M+ rounds in 2025, half the 2021 total, as crossover investors retreat from stretched valuations.

ViaNews Editorial Team

February 28, 2026

Source Trace Score12 source documents12 with a live linkVerifiability: High
Tiger Global, SoftBank Cut Mega-Deals 95% as Global Venture Capital Reclaims Lead
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Tiger Global Management and SoftBank Vision Fund cut their large-deal activity by over 95% between 2021 and 2025, shifting mega-round leadership back to traditional venture capital firms worldwide. Crunchbase data shows 1,440 companies raised rounds of $50 million or more in 2025, roughly half the 2021 cohort.

The pullback by these crossover investors has reshaped global dealmaking. Venture capital firms now dominate large financing rounds as private equity players, overindexed in private companies during 2021's boom, scale back across markets. Established VCs are deploying capital at elevated valuations in AI-focused deals, filling the void left by retreating mega-investors.

Tiger Global and SoftBank's withdrawal reverses their 2021 peak, when rapid deployment strategies pushed valuations to unprecedented levels across U.S., European, and Asian markets. Their near-total exit from mega-rounds reflects broader caution about extended exit timelines and uncertain returns for highly-valued private companies globally.

The halving of mega-round volume raises questions about returns. Extended holding periods and persistent IPO challenges from New York to London to Hong Kong complicate exit scenarios for investors backing companies at premium prices. Crunchbase asks: "Will this new cohort deliver outsized returns in coming years?"

Institutional allocators worldwide are adjusting strategies. Makena Capital, managing over $10 billion, exemplifies emerging hedge-oriented approaches among limited partners. The firm's Stripe exposure serves as a portfolio hedge against Visa, since Stripe could use crypto rails to disrupt Visa's payment network, according to Makena's Lara Banks.

The shift toward VC-led deals coincides with AI sector concentration across global markets. Venture firms with domain expertise and longer investment horizons position themselves as preferred partners for AI startups, displacing the rapid-fire strategies that characterized 2021's frothy market. Whether 2025's cohort generates returns matching their valuations will determine if venture capital's resurgence represents structural improvement or another cycle peak.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: High
  1. [1]News articleYahoo Finance· January 19, 2026
    Andreessen Horowitz Makes a $3 Billion Bet Against the AI Bubble
  2. [2]News articleCrunchbase News
    Crunchbase Data: The AI Boom Has Drastically Changed Who’s Funding The Hottest Companies In 2025 Vs. 2021
  3. [3]Press releaseGlobeNewswire· December 22, 2025
    Eos Energy Honors Outgoing Chair Russ Stidolph for Years of Leadership and Investment and Appoints Industry Veteran Joseph Nigro as Chair of the Board of Directors
  4. [4]Press releaseGlobeNewswire· February 19, 2026
    NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
  5. [5]News articleYahoo Finance· November 18, 2025
    ‘Our funds are 20 years old’: limited partners confront VCs’ liquidity crisis
  6. [6]News articleYahoo Finance· February 20, 2026
    The OpenAI mafia: 18 startups founded by alumni
  7. [7]Earnings callNasdaq· February 25, 2026
    Erie Indemnity (ERIE) Q4 2025 Earnings Transcript
  8. [8]News articleYahoo Finance· February 25, 2026
    Oak-Eagle AcquireCo, Inc. Announces Pricing Terms for the Previously Announced Tender Offers and Consent Solicitations for Any and All of Electronic Arts Inc.'s 1.850% Senior Notes Due 2031 and 2.950% Senior Notes Due 2051
  9. [9]Press releaseGlobeNewswire· February 10, 2026
    OnSpark Launches AI-Powered Partnership Engine Built to Replace Guesswork With Verified Growth Opportunities
  10. [10]Press releaseGlobeNewswire· February 23, 2026
    Recyclable Polyethylene-Based Laminates Market Set Projected to Reach USD 5.92 Billion by 2035 with a 9.0% CAGR
  11. [11]News articleYahoo Finance· February 23, 2026
    Ripple CEO: 90% Chance Crypto Bill Passes By April, But What Do Prediction Markets Say?
  12. [12]Press releaseGlobeNewswire· February 25, 2026
    Vopak reports record financial results for 2025 and announces shareholder distributions program of around EUR 1.7 billion through year-end 2030
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com